It was never part of the plan for Boston Scientific (BSX)
to have a sudden return to growth in the third quarter (or 2012, for
that matter), so it's hard for me to be disappointed by the numbers that
the company continues to post. The driving question for investors
continues to be whether the company's seemingly endless restructuring
moves and acquisitions will give it a better platform from which to
grow, and/or whether the transition to new CEO Mike Mahoney will mark a
turning point. Though I'm still skeptical, I have to point out that the
rewards for success could be meaningful from today's level.
Please continue here:
Boston Scientific Offers More Muddle-Through
No comments:
Post a Comment